Overcoming Challenges in Treating Patients With Triple-Negative Breast Cancer

Stacy L. Moulder, MD, discusses the challenges in drug development for triple-negative breast cancer, specifically in the neoadjuvant setting.

Stacy L. Moulder, MD, professor of breast medical oncology at The University of Texas MD Anderson Cancer Center, discusses the challenges in drug development for triple-negative breast cancer (TNBC), specifically in the neoadjuvant setting.

Approximately 50% of patients with TNBC are sensitive to standard chemotherapy, says Moulder, and they do not need the additional toxicities of certain investigational agents.